Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P P Stein

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Diabetes, Obesity & Metabolism|February 16, 2007
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetesR Brazg, L Xu, C Dalla Man, et al.
Metabolism: Clinical and Experimental|June 1, 1989
Insulin resistance in uremia: an in vivo and in vitro studyP P Stein, W A Hunt, C M Johnson, et al.
Diabetes, Obesity & Metabolism|May 15, 2008
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approachL Xu, C Dalla Man, B Charbonnel, et al.
International Journal of Clinical Practice|May 12, 2010
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyT Seck, M Nauck, D Sheng, et al.
Diabetes, Obesity & Metabolism|February 21, 2012
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesL B Katz, J J Gambale, P L Rothenberg, et al.
Clinical Pharmacology and Therapeutics|October 7, 2011
Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjectsL B Katz, J J Gambale, P L Rothenberg, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyJ C N Chan, R Scott, J C Arjona Ferreira, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Diabetes, Obesity & Metabolism|February 16, 2007
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetesR Brazg, L Xu, C Dalla Man, et al.
Metabolism: Clinical and Experimental|June 1, 1989
Insulin resistance in uremia: an in vivo and in vitro studyP P Stein, W A Hunt, C M Johnson, et al.
Diabetes, Obesity & Metabolism|May 15, 2008
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approachL Xu, C Dalla Man, B Charbonnel, et al.
International Journal of Clinical Practice|May 12, 2010
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyT Seck, M Nauck, D Sheng, et al.
Diabetes, Obesity & Metabolism|February 21, 2012
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetesL B Katz, J J Gambale, P L Rothenberg, et al.
Clinical Pharmacology and Therapeutics|October 7, 2011
Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjectsL B Katz, J J Gambale, P L Rothenberg, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyJ C N Chan, R Scott, J C Arjona Ferreira, et al.
Pageof 2